Over the past few years, Qscription Technologies 's founders had the opportunity to work with Healthcare AI and MedTech companies from around the world seeking to enter the U.S. market.
Many arrive with:
✔ Innovative technology
✔ Strong clinical evidence
✔ Talented engineering teams
✔ FDA-cleared products
Yet a surprising number struggle to achieve meaningful commercial adoption.
Why?
Because U.S. healthcare rarely rewards innovation alone.
The reality is that FDA clearance is only one piece of a much larger puzzle.
Many companies spend years preparing for regulatory approval and only begin thinking about commercialization, interoperability, reimbursement, clinical validation, cybersecurity, enterprise integration, and physician adoption after entering the market.
By then, valuable time and resources have often been lost.
Through this series, we'll explore some of the most common lessons Healthcare AI companies learn too late, including:
🔹 Why FDA clearance does not guarantee market adoption
🔹 Why reimbursement strategy often matters more than AI accuracy
🔹 Why interoperability can become a competitive advantage
🔹 Why clinical validation is increasingly more important than benchmark performance
🔹 Why CIOs, IT leaders, and procurement teams influence adoption as much as clinicians
🔹 How emerging frameworks such as PCCP may reshape the future of AI regulation
Healthcare organizations do not simply buy algorithms.
They buy solutions that fit clinical workflows, integrate with existing infrastructure, demonstrate measurable value, and earn trust across multiple stakeholders.
The companies that succeed understand that healthcare adoption is not a regulatory challenge alone.
It is an operational, clinical, technical, and economic challenge.
Over the coming weeks, I'll be sharing practical insights, real-world observations, and lessons learned from working with Healthcare AI companies navigating the U.S. healthcare ecosystem.
I hope you'll join the conversation.
Because sometimes the most important lessons are the ones nobody discusses until it's too late.
#HealthcareAI #MedicalImaging #DigitalHealth #FDA #SaMD #MedTech #HealthcareInnovation #ClinicalValidation #Interoperability #HealthTech #QscriptionTechnologies